



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/926,693	02/01/2002	Chris Polman	A088 US	3229

7590 08/22/2002

Allen A Brookes
Biogen Inc
14 Cambridge Center
Cambridge, MA 02142

[REDACTED] EXAMINER

SPIVACK, PHYLLIS G

[REDACTED] ART UNIT

[REDACTED] PAPER NUMBER

1614

DATE MAILED: 08/22/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/926,693	Applicant(s) Polman
-------------------------------	------------------------

Examiner Phyllis G. Spivack	Art Unit 1614
--------------------------------	------------------



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
 - 2a) This action is FINAL. 2b) This action is non-final.
 - 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.
- Disposition of Claims**
- 4) Claim(s) 1-14 is/are pending in the application.
 - 5) Claim(s) _____ is/are withdrawn from consideration.
 - 6) Claim(s) 1-14 is/are allowed.
 - 7) Claim(s) _____ is/are rejected.
 - 8) Claims _____ is/are objected to.
 - 9) Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.
- 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

- 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

a) The translation of the foreign language provisional application has been received.

- 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 5, 6

- 4) Interview Summary (PTO-413) Paper No(s). _____
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____

Art Unit: 1614

Information Disclosure Statements filed March 12 and May 29, 2002, respectively, Paper Nos. 5 and 6, are acknowledged and have been reviewed.

Claims 1-14 are presented.

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention.

Claim 1 provides for the use of riluzole for preparing a pharmaceutical composition suitable for the treatment of multiple sclerosis, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claim 1 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Art Unit: 1614

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schluep et al., Medecine et Hygiene (abstract).

Schluep teaches the administration of riluzole as therapy for multiple sclerosis with the use of interferon beta-1a, interferon beta-1b and copolymer 1 (copaxone). Since treatment for amyotrophic lateral sclerosis is disclosed along with treatment of multiple sclerosis, it is unclear from the abstract whether or not the treatments are the same for both disease states. A complete copy of the reference will be provided when it becomes available.

Claims 1-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Arnold et al., WO 98/41882.

Arnold teaches the administration of a pharmaceutical composition comprising riluzole to treat neurodegenerative diseases for which N-acetylaspartate decline has been observed, as in multiple sclerosis. In particular, acute exacerbations of MS are highlighted. See page 6, lines 8-13. The claims differ in that Arnold does not disclose specific additional specific agents for the treatment of multiple sclerosis nor optimal dosages. However, one skilled in the neurology art would have been motivated to administer riluzole to treat primary progressive MS, secondary

Art Unit: 1614

progressive MS and relapsing-remitting MS in view of Arnold's teaching. Such would have been obvious in the absence of evidence to the contrary because riluzole has been established as demonstrating action directed at neurons of patients suffering from neurological diseases wherein an increase in N-acetylaspartate is demonstrated and is associated with a positive effect. The determination of optimal dosages is a parameter well within the purview of those skilled in the art. The administration of multiple therapeutic agents is conventional in treating multiple sclerosis.

No claim is allowed.

Any inquiry concerning this communication should be directed to Phyllis Spivack at telephone number 703-308-4703.

August 21, 2002



**PHYLLIS SPIVACK
PRIMARY EXAMINER**